Some experts have said that macrophages are well-deserved tumor accomplices! Why do you say this?

Tumor-associated macrophages (TAM) are mainly classified into M1 type and M2 type macrophages. M1 type macrophages have an anti-tumor effect, which is capable of distinguishing between tumor cells and normal cells, and finally kills tumor cells by recognizing tumor cells. M2 macrophages mainly play a role in promoting tumor growth, invasion and metastasis.

Studies have shown that:

• Macrophages can induce tumors and promote their progression;

• Macrophage aggregation suggests a poor prognosis in cancer patients;

• Macrophages can create an inflammatory environment that promotes cell mutation and accelerates tumor cell growth.

     ......

As the disease progresses, macrophages also create an environment conducive to cancer cell metastasis, which in turn provides nutritional support for initial proliferation after tumor metastasis.

In order to conquer the macrophages that are being recruited by the tumor, scientists have been working tirelessly.

Just recently, researchers at the University of Pennsylvania's Abramson Cancer found a solution. The study confirmed that macrophages can support the growth and spread of cancer cells and prevent the spread of cancer cells. But most tumors express a signal of CD47 (a "don't eat me") that prevents macrophages from phagocytizing the behavior of tumor cells. 

The researchers found that the metabolism of reconstituted macrophages can suppress this signal and awaken macrophages into work. The new study was published in the January 19 issue of Nature Immunology.

This study reveals the novel role of metabolic pathways in regulating macrophage anti-tumor function and highlights the potential for targeting macrophage metabolism, which can be used for cancer cells to overcome the over-suppression signal by innate immune evasion.

The results show that the central carbon metabolism of macrophages, as a regulator of its anti-tumor function, has the ability to phagocytose tumor cells and is a potential new therapeutic target for stimulating the anti-tumor activity of macrophages.

In recent years, cancer immunotherapy has achieved great success. In 2018, the Nobel Prize in Physiology or Medicine was awarded to American immunologist James P Alison and Japanese immunologist Tasuku Honjo in recognition of their cancer. Contributions in the field of immunotherapy. The great success of immunotherapy has brought hope that cancer can be "cured"!

At present, China's cancer immunotherapy is still in a rapid development stage. However, Japan's immunotherapy in neighboring countries is already at the world's leading level, and it has considerable clinical treatment experience in cell immunotherapy. For more information about Japanese immunotherapy, it is recommended to read: Dry goods | 2018 the world's hottest cancer immunotherapy big inventory!

Review of the history of cancer "immunotherapy" in Japan 

With the development of nearly forty years, Japan's cellular immunotherapy technology has been continuously improved and improved. Cellular immunotherapy is mainly divided into two categories: “ non-specific immunotherapy ” and “ specific immunotherapy ”. Among them, specific immunotherapy is equivalent to “personalized” therapy for specific markers to fight cancer, such as cancer. Vaccines, as well as fusion cell therapies that have recently received the attention of the medical community . Below, the Global Oncologist Network Medical Department will introduce you to Japan's next generation of fusion cell immunotherapy. 

Microscopic photo of fused cells 

Fusion cell therapy

Fusion cell therapy are: the use of dendritic cells, the cancer markers teach information to killer T cells, thereby increasing teach after treatment the number of killer T cells sterility.

There are many kinds of cancer markers (new antigens), and all of them are contained in cancer cells, so it is most appropriate to use the patient's own cancer cells. In addition, the use of interleukin 12 as an adjuvant can also effectively increase the number of killer T cells.

At present, this fusion cell therapy in Japan has been improved, and now it is possible to target multiple cancer antigens carried by cancer cells. To this end, we only need to create a variety of CTLs that can attack various characteristics of cancer cells (cytotoxic T Cells), it is sufficient to provide information on a variety of cancer cells (= cancer antigens) to dendritic cells. 

Case presentations experienced in clinical research

The patient was a 40-year-old man who complained of dizziness and was diagnosed with glioblastoma multiforme (the most malignant 

Type of brain tumor, the patient experienced a recurrence of postoperative brain tumors, but the patient's tumor was significantly reduced after nearly three months of fusion cell therapy.

How to go to Japan for fusion cell immunotherapy?

The Global Oncologist Network expert consultation can help your patients assess whether they are suitable for fusion cell therapy. As a well-known cancer diagnosis and treatment consulting and service platform in China, Global Oncologist Network has been committed to providing first-class anti-cancer services for cancer patients in China, including the latest anti-cancer technology and top cancer expert resources, and set up the largest oncology consultation center in China. Cooperated with famous tumor consultation centers and experts in the United States, Japan, and Europe, and became the most trusted expert in cancer diagnosis and treatment services in China.

Written at the end

We believe that with the continuous improvement of immunotherapy technology and the continuous exploration of scientists in the field of immunotherapy, we believe that immunotherapy is expected to turn cancer into a chronic disease!